Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer

Gynecologic Oncology

Volumn 131, Issue 2, 2013, Pages 368-373

  Argenta, Peter A ^a   Um, Inhwa ^b   Kay, Charlene ^b   Harrison, David ^c   Faratian, Dana ^b   Sueblinvong, Thanasak ^a   Geller, Melissa A ^a   Langdon, Simon P ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Biological therapy; Endocrine therapy; Estrogen receptor; Fulvestrant; Ovarian cancer; Vimentin

Indexed keywords

ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE 2ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GOSERELIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 75; LETROZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; SOMATOMEDIN BINDING PROTEIN; TAMOXIFEN; TREFOIL FACTOR 1; TREFOIL PEPTIDE; UBIQUITIN CONJUGATING ENZYME E2; UNCLASSIFIED DRUG; UROKINASE; VIMENTIN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY; TREATMENT OUTCOME; TREATMENT RESPONSE;

BIOLOGICAL THERAPY; ENDOCRINE THERAPY; ESTROGEN RECEPTOR; FULVESTRANT; OVARIAN CANCER; VIMENTIN;

ANTINEOPLASTIC AGENTS, HORMONAL; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84886098299     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.07.099     Document Type: Article

References (33)

1. G.J. Kelloff, and C.C. Sigman Cancer biomarkers: selecting the right drug for the right patient Nat Rev Drug Discov 11 2012 201 214
2. J.F. Smyth, C. Gourley, G. Walker, M.J. MacKean, A. Stevenson, and A.R. Williams Antiestrogen therapy is active in a selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients Clin Cancer Res 13 2007 3617 3622
3. P.A. Argenta, S.G. Thomas, P.L. Judson, L.S. Downs Jr., M.A. Geller, and L.F. Carson A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer Gynecol Oncol 113 2 2009 205 209
4. S.P. Langdon, A. Ritchie, K. Young, A.J. Crew, V. Sweeting, and T. Bramley Contrasting effects of17h-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo Int J Cancer 55 1993 459 464 [7]
5. S.P. Langdon, G.L. Hirst, E.P. Miller, R.A. Hawkins, A.L. Tesdale, and J.F. Smyth The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines J Steroid Biochem Mol Biol 50 1994 131 135
6. S.P. Langdon, G.J. Rabiasz, G.L. Hirst, R.J. King, R.A. Hawkins, and J.F. Smyth l. Expression of the heat shock protein HSP27 in human ovarian cancer Clin Cancer Res 1 1995 1603 1609
7. G. Walker, K. MacLeod, A.R. Williams, D.A. Cameron, J.F. Smyth, and S.P. Langdon Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer Gynecol Oncol 106 3 2007 461 468
8. R.L. Camp, G.G. Chung, and D.L. Rimm Automated subcellular localization and quantification of protein expression in tissue microarrays Nat Med 8 11 2002 1323 1327
9. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
10. A.E. Guppy, and G.J.S. Rustin CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 7 2002 437 443
11. S.P. Langdon, M.M. Hawkes, S.S. Lawrie, R.A. Hawkins, A.L. Tesdale, and A.J. Crew Oestrogen receptor expression and the effects of estrogen and tamoxifen on the growth of human ovarian carcinoma cell lines Br J Cancer 62 1990 213 216
12. S.P. Langdon, A.J. Crew, A.A. Ritchie, M. Muir, A. Wakeling, and J.F. Smyth Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model Eur J Cancer 30A 1994 682 686
13. J.C. Chura, C.H. Blomquist, H.S. Ryu, and P.A. Argenta Estrone sulfatase activity in patients with advanced ovarian cancer Gynecol Oncol 112 1 2009 205 209
14. A. Bowman, H. Gabra, S.P. Langdon, A. Lessells, M. Stewart, and A. Young CA-125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup Clin Cancer Res 8 2002 2233 2239
15. P. Masiakowski, R. Breathnach, J. Bloch, F. Gannon, A. Krust, and P. Chambon Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line Nucleic Acids Res 10 1982 7895 7903
16. G. Viale, M. Gambacorta, P. Dell'Orto, and G. Coggi Coexpression of cytokeratins and vimentin in common epithelial tumors of the ovary: an immunocytochemical study of eighty-three cases Virchows Arch A Pathol Anat Histopathol 413 2 1988 91 101
17. J. Ulirsch, C. Fan, G. Knafl, M.J. Wu, B. Coleman, and C.M. Perou Vimentin DNA methylation predicts survival in breast cancer Breast Cancer Res Treat 137 2 2013 383 396
18. D. Coppola, L. Fu, S.V. Nicosia, S. Kounelis, and M. Jones Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma Hum Pathol 29 1998 455 462
19. C. Bossard, M. Busson, D. Vindrieux, F. Gaudin, V. Machelon, and M. Brigitte Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer PLoS One 7 9 2012 e44787
20. Y.-K. Leung, Y. Gao, K.-M. Lau, X. Zhang, and S.-M. Ho ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-B/NFKB crosstalk Neoplasia 8 2006 242 249
21. E.R. Prossnitz, L.A. Sklar, T.I. Oprea, and J.B. Arterburn GPR30: a novel therapeutic target in estrogen-related disease TIPS 29 2008 116 123
22. J.A. Hurteau, M.F. Brady, K.M. Darcy, W.P. McGuire, P. Edmonds, and M.L. Pearl Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study Gynecol Oncol 119 3 2010 444 450
23. J. Hasan, N. Ton, S. Mullamitha, A. Clamp, A. McNeilly, and E. Marshall Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer Br J Cancer 93 6 2005 647 651
24. J.L. Belinson, M. McClure, and G. Badger Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma Gynecol Oncol 28 2 1987 151 155
25. S. Wilailak, V. Linasmita, and S. Srisupundit Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer Anticancer Drugs 12 9 2001 719 724
26. P.H. Wiernik, E.S. Greenwald, H. Ball, J.A. Young, and S. Vogl High-dose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment: Eastern Cooperative Oncology Group Study PD884 Am J Clin Oncol 21 6 1998 565 567
27. J. Malfetano, J.B. Beecham, B.N. Bundy, and K.D. Hatch A phase II trial of medroxyprogesterone acetate in epithelial ovarian cancers. A Gynecologic Oncology Group study Am J Clin Oncol 16 2 1993 149 151
28. M.G. del Carmen, A.F. Fuller, U. Matulonis, N.K. Horick, A. Goodman, and L.R. Duska Phase II trial of anastrozole in women with asymptomatic müllerian cancer Gynecol Oncol 91 3 2003 596 602
29. C.A. Papadimitriou, S. Markaki, J. Siapkaras, G. Vlachos, E. Efstathiou, and I. Grimani Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study Oncology 66 2 2004 112 117
30. P.T. Ramirez, K.M. Schmeler, M.R. Milam, B.M. Slomovitz, J.A. Smith, and J.J. Kavanagh Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum Gynecol Oncol 110 1 2008 56 59
31. A. du Bois, W. Meier, H.J. Lück, G. Emon, V. Moebus, and W. Schroeder Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer Ann Oncol 13 2 2002 251 257
32. D.S. Miller, M.F. Brady, and R.J. Barrett A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma A Gynecologic Oncology Group study Am J Clin Oncol 15 2 1992 125 128
33. S. Tumolo, B.R. Rao, M.E. van der Burg, J.P. Guastalla, J. Renard, and J.B. Vermorken Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study Eur J Cancer 30A 7 1994 911 914